Lunai Bioworks Regains Nasdaq Minimum Bid Price Compliance After Reverse Split
LNAI has more than doubled off its 52-week low of $1.21.
Summary
Lunai Bioworks announced it has regained compliance with Nasdaq's minimum bid price rule, removing an immediate delisting threat, though it will be under a one-year monitoring period.
Key Events · Corporate Governance and Compliance · LNAI
-
Regained Nasdaq Compliance
The company received a letter from Nasdaq confirming it has regained compliance with the minimum bid price rule ($1.00 per share), resolving a prior delisting threat.
-
Mandatory Monitoring Period
Lunai Bioworks will be subject to a one-year mandatory Panel monitor. During this period, any future non-compliance with the bid price rule would result in a delisting determination without additional cure periods.
-
Follows Reverse Stock Split
This compliance was achieved following the 1-for-8 reverse stock split executed on May 22, 2026, which was intended to increase the share price to meet Nasdaq's requirements.
Analysis · LNAI · Life Sciences
Lunai Bioworks has successfully regained compliance with Nasdaq's minimum bid price rule, resolving a significant delisting threat that has been a major concern for investors. This positive development follows the 1-for-8 reverse stock split executed on May 22, 2026, which was specifically aimed at boosting the share price to meet this requirement. While the immediate delisting risk is mitigated, the company will be subject to a mandatory one-year monitoring period, meaning any future non-compliance with the bid price rule would lead directly to a delisting determination without further cure periods.
At the time of this filing, LNAI was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $1.21 to $31.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.